ARRIVE Trial: Daily Aspirin Did Not Lower First Heart Attack, Stroke Risk – APhA submits compounding comments to FDA.

1594_GraphicImage_051115Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

ARRIVE Trial: Daily Aspirin Did Not Lower First Heart Attack, Stroke Risk – APhA submits compounding comments to FDA. – (866) 348-2889.

Daily aspirin did not reduce the occurrence of major cardiovascular events a study of more than 12,500 participants considered to be at risk, according to the results of the ARRIVE trial, presented this week at the European Society of Cardiology (ESC) Meeting in Munich, Germany.

Michael Gaziano, MD, a preventive cardiologist at Brigham and Women’s Hospital, presented findings from the Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) study, which was sponsored by Bayer. The study was a randomized, controlled clinical trial of the use of daily aspirin to prevent a first cardiovascular event among more than 12,500 participants considered to be at moderate cardiovascular risk.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.